HLB Therapeutics Falls 3.53% to 2,460 Won... Whether It Can Rebound After Hitting Upper Limit on the 28th Draws Attention
HLB Therapeutics continues to decline on its own even as the broader index rises. As of the afternoon of the 1st, HLB Therapeutics is trading at 2,460 won, down 90 won from the previous trading day, a decline of about 3.53%. The stock's weakness has continued since it hit the upper price limit on

HLB Therapeutics continues to decline on its own even as the broader index rises.
As of the afternoon of the 1st, HLB Therapeutics is trading at 2,460 won, down 90 won from the previous trading day, a decline of about 3.53%.
The stock's weakness has continued since it hit the upper price limit on September 28. As it has failed to sustain upward momentum immediately after the limit-up, attention is focused on whether the share price can recover.
While the KOSPI and KOSDAQ both showed gains on the day, only HLB Therapeutics showed weakness, with the market index and the individual stock moving in opposite directions.
Given that the uptrend has not continued since the limit-up, both the possibility of further declines and any rebound attempt should be watched together. However, based on the current price movement alone, it is difficult to attribute the decline definitively to profit-taking or the impact of a specific catalyst.
Whether the stock can narrow its intraday losses and whether weakness will persist through the close are the key points to watch for the remaining trading hours.
[This article was written based on provided market price information and is not intended to solicit investment. Stock prices and target prices may fluctuate depending on market conditions and corporate performance. Investment decisions and the responsibility for them rest with the investor. AI was used for some sentences and data organization.]
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.



